Global CAR-T Therapies for Autoimmune Diseases Market - Trends and Forecast Till 2035

CAR-T THERAPIES FOR AUTOIMMUNE DISEASES MARKET: OVERVIEW

The global CAR-T therapies for autoimmune disease market is valued at USD 2.14 billion in the current year and is projected to reach USD 8.02 billion by 2035, representing a CAGR of 15.8% during the forecast period.

CAR-T Therapies for Autoimmune Diseases Market: Growth and Trends

Autoimmune diseases have emerged as the most promising new application area for CAR-T cell therapy beyond oncology. The therapeutic rationale lies in CD19-directed “B-cell reset,” where CAR-T therapy deeply depletes autoreactive and memory B cells, enabling regeneration of a naïve B-cell repertoire with fewer disease-driving autoantibody-producing clones than conventional biologics such as rituximab or belimumab.

Notably, Cabaletta Bio's rese-cel program has reported encouraging early responses across five simultaneous RESET trials spanning lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Meanwhile, Kyverna's miv-cel has produced registrational-quality data in stiff person syndrome and interim Phase 2 results in generalized myasthenia gravis. Cartesian Therapeutics is pursuing a differentiated approach with Descartes-08, an mRNA-based, transiently expressed CAR-T therapy designed to avoid the lymphodepleting chemotherapy and hospitalization associated with conventional autologous CAR-T manufacturing.

The acquisition of autoimmune-focused CAR-T platforms by major pharmaceutical companies reflects the broader wave of M&A activity targeting in vivo cell engineering technologies. AbbVie, Bristol Myers Squibb, and Roche have each acquired platform companies with CD19-directed autoimmune programs, underscoring the growing strategic importance of autoimmune indications as a commercial opportunity alongside oncology in the next generation of CAR-T therapies.

Growth Drivers: Factors Fueling Market Expansion

The CAR-T therapies for autoimmune diseases market is being propelled by an unprecedented convergence of positive early clinical data, a rapidly expanding pipeline of clinical-stage assets, and continued manufacturing innovation. Registrational and Phase 2 readouts in stiff person syndrome, generalized myasthenia gravis, and lupus have demonstrated the potential for durable, treatment-free remission after a single dose, a profile that current biologics and small-molecule immunosuppressants cannot match.

Commercial interest is supported by a large unmet patient population, with an estimated 400,000-600,000 patients globally with SLE who have failed two or more standard therapies. Emerging approaches, including transient mRNA CAR-T and in vivo CAR-T platforms, could reduce lymphodepletion, manufacturing complexity, treatment burden, and cost, potentially expanding patient and treatment-center access.

Market Challenges: Critical Barriers Hindering Progress

Despite strong clinical momentum, the market faces meaningful barriers to broad commercialization. No CAR-T therapy has yet received approval for an autoimmune indication, leaving regulators to establish appropriate efficacy benchmarks, trial designs, and long-term safety requirements. This is particularly important because autoimmune patients are generally younger and healthier than oncology CAR-T recipients, making risks such as cytokine release syndrome, neurotoxicity, and prolonged B-cell aplasia less acceptable.

The high cost and complexity of patient-specific autologous CAR-T manufacturing remain key access barriers, particularly in chronic, non-fatal autoimmune diseases where its economic value must be demonstrated against established biologic therapies through payer negotiations. Competition from next-generation B-cell-depleting biologics, CD19/CD3 bispecific antibodies, and other T-cell engagers is also intensifying. Consequently, developers must demonstrate that a one-time CAR-T infusion offers a meaningfully better benefit-risk and total cost of care profile to justify premium pricing.

CAR-T Therapies for Autoimmune Diseases Market: Key Insights

This report examines the current state of the global CAR-T therapies for autoimmune diseases market and identifies the growth opportunities available to biopharmaceutical innovators, CDMOs, and investors. Some of the key findings include:

• Kyverna Therapeutics' miv-cel is positioned to become the first CAR-T cell therapy approved for an autoimmune indication, with a biologics license application for stiff person syndrome planned following registrational data showing improved mobility and elimination of chronic immunotherapy after a single infusion.
• Cabaletta Bio holds the broadest clinical-stage autoimmune CAR-T portfolio, running five simultaneous RESET Phase 1/2 trials in lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris, supported by multiple FDA Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations.
• Systemic lupus erythematosus (including lupus nephritis) represents the leading disease-indication segment, projected to grow at a high CAGR through 2035 on the strength of an estimated 400,000-600,000 addressable patients who have failed two or more prior lines of therapy.
• Manufacturing differentiation is emerging as a key competitive axis transient, non-integrating mRNA CAR-T platforms such as Cartesian Therapeutics' Descartes-08 aim to avoid lymphodepleting chemotherapy altogether, while in-vivo delivered platforms from AbbVie/Capstan and Bristol Myers Squibb/Orbital aim to eliminate ex-vivo cell manufacturing entirely.
• Big pharma has committed more than USD 5 billion in disclosed acquisition value to autoimmune-focused CAR-T and adjacent cell-engineering platforms since late 2024, led by Roche/Poseida, AbbVie/Capstan, and Bristol Myers Squibb/Orbital, validating autoimmune disease as a core commercial thesis alongside oncology.
• Competitive positioning is bifurcating into three technology camps: autologous, DNA-integrating CAR-T; transient mRNA CAR-T and in-vivo delivered CAR-T; and in-vivo delivered CAR-T, each carrying distinct manufacturing, durability, safety, and re-dosing profiles that will shape licensing, partnership, and pricing strategy over the next 12-24 months.

Recent Deal Activity Signaling Investor Momentum

Big pharma acquisition activity has accelerated around autoimmune-focused CAR-T and adjacent in-vivo cell-engineering platforms, with more than USD 5 billion in disclosed deal value committed:

• Roche acquires Poseida Therapeutics, gaining allogeneic CAR-T programs spanning oncology, lupus, and multiple sclerosis.
• AbbVie acquires Capstan Therapeutics for its CD19-targeted in vivo CAR-T platform in B-cell-driven autoimmune disease.
• Bristol Myers Squibb acquires Orbital Therapeutics, gaining OTX-201, an in vivo CD19 CAR-T candidate for autoimmune "immune reset".
• Kyverna Therapeutics completes a public offering to fund its planned BLA filing for miv-cel in stiff person syndrome.

Collectively, these transactions underscore sustained strategic-acquirer conviction that CD19-directed "B-cell reset" CAR-T constructs can address chronic autoimmune disease with a durability and depth of response that existing biologics cannot match, and that manufacturing innovation, whether allogeneic, transient mRNA, or in-vivo delivered, will be central to unlocking broad patient access.

Global CAR-T Therapies for Autoimmune Diseases Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Cell Source

• Autologous CAR-T
• Allogeneic (Off-the-Shelf) CAR-T

By Target Antigen

• CD19
• BCMA
• CD20
• Other Targets

By Disease Indication

• Systemic Lupus Erythematosus / Lupus Nephritis
• Idiopathic Inflammatory Myositis
• Systemic Sclerosis
• Generalized Myasthenia Gravis
• Stiff Person Syndrome
• Multiple Sclerosis
• Rheumatoid Arthritis
• Other Autoimmune Indications

By End User

• Hospitals
• Specialty and Academic Treatment Centers
• Ambulatory Infusion Centers

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia-Pacific
• Middle East and North Africa
• Saudi Arabia
• UAE
• Latin America
• Brazil
• Argentina
• Rest of Latin America

CAR-T Therapies for Autoimmune Diseases Market: Key Segment Insights

Systemic Lupus Erythematosus Leads the Indication Landscape

Systemic lupus erythematosus, including lupus nephritis, is the leading disease-indication segment and is projected to grow at a higher CAGR through 2035. This largest share is due to the growing number of patients globally who have failed two or more lines of standard immunosuppressive therapy, and by encouraging early efficacy data reported across multiple sponsor programs.

Neuroimmunology Is Positioned to Deliver the First Approval

Stiff person syndrome and generalized myasthenia gravis, both pursued by Kyverna Therapeutics, are on the most advanced regulatory timelines in the market, with a BLA filing already planned for the approval. A first approval in neuroimmunology is expected to establish the regulatory precedent and reimbursement framework that subsequent rheumatology-focused programs, including those in lupus, myositis, and systemic sclerosis, will follow.

Autologous CAR-T Dominates Current Clinical Activity

Autologous, lentivirally-transduced CAR-T remains the most clinically mature cell source given its direct lineage from approved oncology CAR-T products. However, allogeneic and in-vivo delivered platforms are gaining momentum as developers seek to reduce manufacturing lead time, lymphodepletion requirements, and per-patient cost for a chronic, non-oncology patient population.

North America Dominates the Market

Based on our regional analysis, North America accounted for the highest share of the market, reflecting the concentration of registrational and Phase 2 trial activity among leading developers. On the other hand, Asia-Pacific is expected to grow at a higher CAGR during the forecast period. China-based developers, including AbelZeta, are advancing parallel clinical programs in lupus nephritis, myositis, and stiff person syndrome, positioning Asia-Pacific as an increasingly important contributor to global pipeline activity.

Example Players in the CAR-T Therapies for Autoimmune Diseases Market

• AbelZeta
• AbbVie (Capstan Therapeutics)
• Autolus Therapeutics
• Cabaletta Bio
• Cartesian Therapeutics
• Bristol Myers Squibb Company (Orbital Therapeutics)
• Gilead Sciences (Kite Pharma)
• Roche (Poseida Therapeutics)
• Kyverna Therapeutics
• Novartis
• Sana Biotechnology
• Umoja Biopharma

CAR-T THERAPIES FOR AUTOIMMUNE DISEASES MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: In-depth analysis across cell source, target antigen, disease indication, end user, and geography.
• Competitive Landscape: A detailed assessment of active developers, including platform technology, pipeline stage, and regulatory designation status.
• Company Profiles: Profiles of prominent players, covering platform overview, pipeline, recent financing / M&A history, and strategic partnerships.
• Clinical Analysis: Comparative assessment of efficacy, safety (CRS/ICANS rates), and durability data reported across autologous, allogeneic, mRNA, and in-vivo delivered programs.
• Pipeline Analysis: Clinical and preclinical pipeline mapped by phase of development, target antigen, disease indication, and sponsor.
• Partnerships and Collaborations Analysis: Analysis of licensing deals, co-development agreements, and technology partnerships by year, deal type, and platform.
• Funding and M&A Analysis: A detailed review of venture financing, acquisitions, and licensing transactions, including deal value, structure, and most active acquirers.
• Regulatory Landscape: Assessment of FDA Fast Track, RMAT, and Breakthrough Therapy designations, and anticipated approval timelines by indication.
• SWOT Analysis: Strategic assessment of strengths, weaknesses, opportunities, and threats facing autoimmune CAR-T developers relative to incumbent biologics.
• Future Outlook: Perspective on indication expansion, manufacturing evolution, and anticipated regulatory and reimbursement milestones through 2035.

KEY QUESTIONS ANSWERED IN THIS REPORT

• Which companies and platforms are leading the CAR-T therapies for autoimmune diseases market?
• Which disease indication and region dominate the market today, and which are growing the fastest?
• What are the key clinical and technology trends shaping this market?
• Which program is likely to achieve the first regulatory approval, and on what timeline?
• What are the primary clinical, manufacturing, and regulatory challenges facing developers?
• What is the current and projected future size of the CAR-T therapies for autoimmune diseases market?
• What is the CAGR of this market through 2035?
• How is current and future market opportunity distributed across cell source, target antigen, and disease indication?
• What licensing, partnership, and acquisition opportunities exist for pharmaceutical companies and investors entering this space?

REASONS TO BUY THIS REPORT

This report is designed to give biopharmaceutical companies, investors, and manufacturing partners a decisive analytical edge in a fast-emerging market. Its core differentiators include:

• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates top-down macro assessments against bottom-up, indication-level pipeline and deal data to minimize forecast bias.
• Clinical Data and Regulatory Timeline Lens: Unlike conventional cell therapy landscape reports, this study tracks program-level efficacy, safety, and regulatory designation data to identify which assets are best positioned for the market's first approvals.
• Technology Platform Benchmarking: Comparative evaluation of autologous, allogeneic, transient mRNA, and in-vivo delivered CAR-T platforms, supporting technology diligence for in-licensing, partnership, or in-house platform investment decisions.
• Primary Research-Backed Insights: Findings are informed by review of company disclosures, clinical trial data, and deal documentation, ensuring insights reflect real development and commercial conditions.
• Actionable Segmentation: Multi-parameter segmentation (cell source, construct platform, target antigen, disease indication, end user, geography) enables precise opportunity sizing for any go-to-market, licensing, or investment thesis.

ADDITIONAL BENEFITS

• Complementary data packs covering key market segments
• Content customization available on request
• Detailed report walkthrough session with the research team
• Free report update if the report is 6-12 months old or older